Livia Bernadett Adalbert

Dr. Livia Bernadett Adalbert

University of Szeged, Szeged, Csongrád, Hungary
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
SKS P Yamini Kanti
S P Yamini Kanti
Ildikó CsókaIldikó Csóka
Ildikó Csóka
OLOrsolya Jójártné Laczkovich
Orsolya Jójártné Laczkovich
LALivia Bernadett Adalbert
Livia Bernadett Adalbert
In recent years, we have witnessed prominent improvements in urinary catheter coatings to tackle the commonly occurring catheter-associated urinary tract infection (CAUTI) in catheterized patients. CAUTIs are claimed to be one of the most frequent nosocomial infections that can lead to various complications, from catheter encrustation to severe septicaemia and pyelonephritis. Besides general prevention hygienic strategies, antimicrobial-coated urinary catheters show great potential in the prevention of urinary catheter-associated complications. The aim of this review is to present and evaluate recent updates on the development of antimicrobial urinary catheters in the context of the aetiology of urinary malfunction. Subsequently, we shed some light on future perspectives of utilizing 3D printing and the surrounding regulatory directions.

16 November 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
LALivia Bernadett Adalbert
Livia Bernadett Adalbert
SKS P Yamini Kanti
S P Yamini Kanti
OLOrsolya Jójártné Laczkovich
Orsolya Jójártné Laczkovich
HAHussein Akel
Hussein Akel
Ildikó CsókaIldikó Csóka
Ildikó Csóka
The vast scope of 3D printing has ignited the production of tailored medical device (MD) development and catalyzed a paradigm shift in the health-care industry, particularly following the COVID pandemic. This review aims to provide an update on the current progress and emerging opportunities for additive manufacturing following the introduction of the new medical device regulation (MDR) within the EU. The advent of early-phase implementation of the Quality by Design (QbD) quality management framework in MD development is a focal point. The application of a regulatory supported QbD concept will ensure successful MD development, as well as pointing out the current challenges of 3D bioprinting. Utilizing a QbD scientific and risk-management approach ensures the acceleration of MD development in a more targeted way by building in all stakeholders’ expectations, namely those of the patients, the biomedical industry, and regulatory bodies.